Luxbright AB (publ) (LXB.ST)
SEK 0.82
(-3.55%)
SEK 0.82
(-3.55%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 206.02 Thousand SEK | 0.0% |
| 2022 | 206.02 Thousand SEK | -81.24% |
| 2021 | 1.09 Million SEK | -39.19% |
| 2020 | 1.8 Million SEK | -12.38% |
| 2019 | 2.06 Million SEK | -16.53% |
| 2018 | 2.46 Million SEK | -77.03% |
| 2017 | 10.74 Million SEK | 498.45% |
| 2016 | 1.79 Million SEK | 124.47% |
| 2015 | 800 Thousand SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 205 Thousand SEK | -0.5% |
| 2024 Q2 | 205 Thousand SEK | 0.0% |
| 2023 Q3 | 206.02 Thousand SEK | 0.01% |
| 2023 Q4 | 206.02 Thousand SEK | 0.0% |
| 2023 Q1 | 206 Thousand SEK | -0.01% |
| 2023 Q2 | 206 Thousand SEK | 0.0% |
| 2023 FY | 206.02 Thousand SEK | 0.0% |
| 2022 Q4 | 206.02 Thousand SEK | 0.0% |
| 2022 Q3 | 206.02 Thousand SEK | -75.56% |
| 2022 Q2 | 843 Thousand SEK | 0.0% |
| 2022 Q1 | 843 Thousand SEK | -23.23% |
| 2022 FY | 206.02 Thousand SEK | -81.24% |
| 2021 Q1 | 1.35 Million SEK | -25.07% |
| 2021 Q3 | 1.09 Million SEK | -18.85% |
| 2021 FY | 1.09 Million SEK | -39.19% |
| 2021 Q4 | 1.09 Million SEK | 0.01% |
| 2021 Q2 | 1.35 Million SEK | 0.0% |
| 2020 Q4 | 1.8 Million SEK | -0.02% |
| 2020 Q2 | 1.97 Million SEK | -0.02% |
| 2020 Q1 | 1.97 Million SEK | -4.12% |
| 2020 FY | 1.8 Million SEK | -12.38% |
| 2020 Q3 | 1.8 Million SEK | -8.59% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | 2.06 Million SEK | -16.53% |
| 2019 Q4 | 2.06 Million SEK | -0.01% |
| 2019 Q2 | 2.31 Million SEK | 0.0% |
| 2019 Q3 | 2.06 Million SEK | -11.03% |
| 2018 FY | 2.46 Million SEK | -77.03% |
| 2017 FY | 10.74 Million SEK | 498.45% |
| 2016 FY | 1.79 Million SEK | 124.47% |
| 2015 FY | 800 Thousand SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.986% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.986% |
| Arcoma AB | 1.92 Million SEK | 89.309% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 99.513% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.988% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 99.643% |
| CellaVision AB (publ) | 28.66 Million SEK | 99.281% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | 7.613% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | 88.247% |
| Duearity AB (publ) | 2.94 Million SEK | 92.992% |
| Dignitana AB (publ) | 6.07 Million SEK | 96.61% |
| Episurf Medical AB (publ) | 2.3 Million SEK | 91.042% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.995% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 96.757% |
| Iconovo AB (publ) | 4.9 Million SEK | 95.801% |
| Integrum AB (publ) | 4.84 Million SEK | 95.747% |
| Mentice AB (publ) | 2.14 Million SEK | 90.391% |
| OssDsign AB (publ) | 214 Thousand SEK | 3.727% |
| Paxman AB (publ) | 2.53 Million SEK | 91.863% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | 93.142% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 95.07% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 98.927% |
| Sedana Medical AB (publ) | 1.01 Million SEK | 79.642% |
| Senzime AB (publ) | 8.57 Million SEK | 97.598% |
| SpectraCure AB (publ) | 4.39 Million SEK | 95.314% |
| Stille AB | 38.06 Million SEK | 99.459% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.989% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 99.027% |